Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Rui Bao *The Second Affiliated Hospital of Wannan Medical College, Wuhu, 241000, China.
Wanying Shi *The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China.
Hongbo Bao *Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Tonghua Zhang *The Second Affiliated Hospital of Wannan Medical College, Wuhu, 241000, China. zth7607@163.com.
Xueying Li *Department of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China. xueyingli0616@163.com.
Wencai Ding *The Second Affiliated Hospital of Wannan Medical College, Wuhu, 241000, China. dingneurology@gmail.com.
A4 and LEARN Study; The Health and Aging Brain Study (HABS-HD) Study Team
Funding
The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
The Health & Aging Brain Study - Health Disparities (HABS-HD)U19AG078109 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI LEIGH A JOHNSON · 2022 to 2026
$181.1M
RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
Health and Aging Brain among Latino Elders (HABLE-AT(N)) StudyR01AG058533 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI JOHNSON, LEIGH A, O'BRYANT, SID E · 2020 to 2025
$45.4M
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8M
TR&D3: Intrinsic Surface MappingP41EB015922 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TOGA, ARTHUR W · 2012 to 2022
$14.1M
Health Disparities in Alzheimer's Disease and Mild Cognitive Impairment among Mexican AmericansR01AG054073 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI O'BRYANT, SID E, TOGA, ARTHUR W · 2017 to 2021
$12.6M
Epigenetic Risk Factors for AD Age at Onset and Health Disparities: HABLE Epigenetics StudyR01AG070862 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI BARBER, ROBERT CLINTON · 2021 to 2025
$3.4M
Department of Education of Liaoning Province LJ212510161032High-level Talent Recruitment Program of Wannan Medical College EYR202306Liaoning Provincial Natural Science Foundation Joint Funds Project 2024-BSLH-047Major Scientific Research Project of the Anhui Province Department of Education 2024AH040242National Natural Science Foundation of China 82501744NIA NIH HHS R01 AG054073NIA NIH HHS R01 AG058533NIA NIH HHS R01 AG063689NIA NIH HHS R01 AG070862NIA NIH HHS U19 AG010483NIA NIH HHS U19 AG078109NIA NIH HHS U24 AG057437NIBIB NIH HHS P41 EB015922Research Start-up Fund for High-level Talent at the Second Affiliated Hospital of Wannan Medical College GRK202510Research Start-up Fund for High-level Talent at the Second Affiliated Hospital of Wannan Medical College GRK202511
6 · The paper itself
Abstract
backgroundEarly detection of Alzheimer's disease (AD) pathology in cognitively unimpaired individuals is critical for preclinical intervention. Plasma biomarkers, especially phosphorylated tau217 (p-tau217), are promising predictors of amyloid-β (Aβ) accumulation.
methodsIn this cohort study, we analyzed data from cognitively unimpaired older adults in the A4 and LEARN studies (n = 1,407), comprising 452 participants with Aβ positron emission tomography (PET)-negative status and 955 participants with Aβ PET-positive status. We evaluated the accuracy of plasma biomarkers (p-tau217, p-tau181, Aβ42/40 ratio, and others) in predicting Aβ PET positivity using receiver operating characteristic analysis, comparing covariate-adjusted individual biomarker and biomarker-ratio models with a multivariable combined model integrating plasma biomarkers and covariates. (age, sex, apolipoprotein E [APOE] ε4 genotype).
resultsPlasma p-tau217 showed the strongest individual association with Aβ PET status (area under the curve [AUC], 0.85). A combined model integrating p-tau217, p-tau181, Aβ42, age, sex, and APOE ε4 achieved the highest overall discrimination (AUC, 0.87), although the improvement over the covariate-adjusted p-tau217 model was modest.
conclusionsPlasma p-tau217 showed the strongest individual performance for predicting Aβ PET positivity in cognitively unimpaired older adults. Adding other plasma biomarkers and clinical covariates provided a modest incremental improvement in classification performance. These findings support blood-based prescreening as a potential enrichment approach, while indicating that confirmatory amyloid assessment remains necessary when definitive Aβ status is required.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Plasma p-tau217, p-tau181, and Aβ42 predict amyloid PET positivity in cognitively unimpaired adults. · full record | OpenQuestion